색전 입자 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the embolization particle market size is projected to expand from USD 2.19 billion in 2025 and USD 2.42 billion in 2026 to USD 4.15 billion by 2031, registering a CAGR of 11.41% between 2026 to 2031.

This report is Segmented by Product Type (Radioembolization Spheres, and More), Embolic Material (Synthetic, Natural), Mode of Action (Permanent, Temporary/Resorbable), Application (Oncology, Urology, and More), End User (Hospitals, Ascs, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Embolization Particle Market Trends and Insights

Rising Liver Cancer and Embolization Case Volumes

The embolization particle market is closely tied to liver cancer incidence because transarterial therapies remain central for patients who present beyond the surgical window. Global liver cancer cases rose 26% between 2010 and 2021 to 529,202, and hepatocellular carcinoma accounted for 80% to 85% of that burden, which directly supports higher use of embolization in unresectable disease. Liver cancer also remains one of the leading causes of cancer death worldwide, and its absolute burden continues to rise with aging populations even where age-standardized rates have stabilized or declined. China remains especially important because national clinical literature states that 64% of HCC patients are diagnosed at intermediate to advanced stages, where TACE is recommended as first-line treatment for CNLC IIb and IIIa disease. A second demand stream comes from liver metastases, since colorectal cancer continues to generate a large pool of patients who may later require embolization-based control of hepatic lesions.

Advances in Radiopaque, Calibrated, and Drug-Eluting Particles

The embolization particle market is also moving forward because product design is becoming more precise in how particles are visualized, distributed, and loaded with therapy. A 32-study meta-analysis covering 4,367 HCC patients found that DEB-TACE improved overall survival by 3.54 months and progression-free survival by 3.07 months versus conventional TACE, which supports continued clinical conversion toward drug-eluting platforms. Boston Scientific's DC Bead LUMI and LC Bead LUMI introduced inherent radiopacity through covalently bound iodine, which allows physicians to visualize particle delivery through CT, fluoroscopy, and cone-beam CT during the procedure itself. A parallel development came from absorbable microspheres made with hyaluronic acid and microfluidic manufacturing, which showed vessel-adaptive adhesion and more than 90% degradation within 2 months in preclinical models, pointing to broader future use where permanent occlusion is not preferred. Better particle uniformity is also improving procedural predictability, which matters to hospitals because more precise endpoint control can limit waste, reduce repeat intervention risk, and strengthen the clinical case for premium embolics.

High Procedure Costs and Uneven Reimbursement

The embolization particle market still faces meaningful friction from cost because advanced embolization procedures require expensive consumables, trained teams, imaging support, and, in the case of Y-90, complex planning steps. A time-driven activity-based costing study of 123 uterine artery embolization procedures found that embolic agents represented 51% of consumable costs, which made them the single largest cost component in the case bundle. That kind of cost profile pushes hospitals and value-analysis committees to ask whether premium-calibrated or radiopaque particles can reduce procedure time, repeat use, or downstream complications enough to justify higher prices. Reimbursement remains uneven across settings and indications, which can delay adoption even when physicians support the clinical case for embolization. This is why established products with stronger real-world evidence, longer registries, and clearer coding support often displace newer entrants that lack the same economic proof package.

Other drivers and restraints analyzed in the detailed report include:

1. FDA Expansion of SIR-Spheres for Unresectable HCC
2. Guideline Mainstreaming of Prostate Artery Embolization for BPH/LUTS
3. Interventional Radiology Workforce Shortages

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Radioembolization spheres held the largest share at 36.93% in 2025, which gave this category the leading revenue position in the embolization particle market. This lead reflects the established place of Y-90 therapies in liver cancer care, especially in centers that already have dosimetry expertise, nuclear pharmacy access, and multidisciplinary oncology workflows. The July 2025 FDA approval of SIR-Spheres for unresectable HCC widened the resin microsphere opportunity, while TheraSphere continued to support the glass microsphere base in high-acuity programs. The combination of these two platforms gives hospitals more treatment flexibility and supports continued physician training across both established and expanding radioembolization programs.

Drug-eluting beads are forecast to grow at a 12.84% CAGR through 2031, making them the fastest-expanding product type in the embolization particle market. Their momentum is linked to stronger comparative evidence, since a meta-analysis of 4,367 HCC patients found that DEB-TACE improved both overall survival and progression-free survival versus conventional TACE. A randomized clinical trial in HCC with portal vein tumor thrombus also reported median overall survival of 12 months with CalliSphere 100 to 300 µm beads versus 7 months with conventional TACE. Embolic microspheres, PVA particles, and gelatin sponge still hold durable roles in fibroid embolization, hemorrhage control, and pre-operative devascularization, which keeps innovation in the embolization particle industry spread across several procedural niches rather than concentrated in one format.

Synthetic materials commanded 56.16% share in 2025, which placed them at the center of the embolization particle market across oncology and vascular intervention. Their lead comes from the long clinical history of PVA, acrylic, PMMA, PEG hydrogel, resin, and glass platforms, all of which offer predictable sizing, controlled delivery, and familiar handling in microcatheter-based procedures. Synthetic particles also benefit from stronger post-market datasets, which give regulators and hospital committees more confidence when these products are considered for wider protocol adoption. In practice, this means suppliers with standardized synthetic platforms are better placed to support repeat purchasing, physician preference, and multi-indication use.

Natural materials are projected to grow at a 12.39% CAGR through 2031, reflecting rising interest in temporary occlusion and repeat-procedure flexibility within the embolization particle market. Instylla's Tembo Embolic System received FDA 510(k) clearance in January 2025 as a bioresorbable dry gelatin particle for hypervascular tumor and peripheral vascular embolization, which gave this part of the category a clearer commercial foothold in the United States. The appeal of gelatin and starch-based materials is strongest where recanalization can be clinically useful, such as selected gynecologic, musculoskeletal, or staged embolization settings. Even so, the embolization particle industry is likely to remain synthetic-heavy over the medium term because permanent and calibrated platforms still align more closely with the needs of high-volume oncology practice.

Geography Analysis

North America held 36.05% of global revenue in 2025, and the embolization particle market in the region remained the largest worldwide. The United States anchors this lead because it has both established radioembolization infrastructure and high-volume interventional radiology practices that can support advanced oncologic procedures. The July 2025 FDA approval of SIR-Spheres for unresectable HCC widened physician choice and strengthened the commercial position of Y-90 therapy in liver-directed care. Outpatient migration is also more advanced here, with 85% of North American radioembolization procedures performed as outpatient cases versus 13% in Europe, which helps volume growth without matching hospital bed expansion. Canada and Mexico remain smaller, but both benefit from growing tertiary care capability and referral pathways that gradually widen access to embolization procedures.

Europe is a mature region, and the embolization particle market there is shaped more by evidence-led adoption than by abrupt volume surges. Germany, the United Kingdom, France, Italy, and Spain continue to anchor regional demand through dense specialist networks and active interventional oncology practice. A global survey found that 84% of European sites used personalized dosimetry for radioembolization versus 71% in North America, which favors suppliers that can support software integration, imaging alignment, and training depth. EU MDR requirements also place heavier post-market evidence demands on suppliers, which tends to support larger manufacturers with established clinical registries and stronger regulatory teams.

Asia-Pacific is the fastest-growing region, with the embolization particle market forecast to expand at a 15.36% CAGR through 2031. China remains central because liver cancer burden is high and national clinical literature recommends TACE as first-line treatment for CNLC IIb and IIIa disease, where surgery is not feasible. Japan supports stable procedural demand through its updated 2025 HCC guidance and reimbursement recognition for DC Bead in arterial chemoembolization. Middle East and Africa and South America are smaller today, but rising tertiary care investment, medical tourism, and local commercialization efforts still support long-term expansion across these emerging regions.

1. ABK Biomedical Inc.
2. Boston Scientific
3. Cardiolink Science (Shenzhen) Medical Technology Development Co., Ltd.
4. Cook Group
5. CrannMed Ltd.
6. Endovastec (Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.)
7. IMBiotechnologies Ltd.
8. Instylla, Inc.
9. Magle Pharmacept GmbH
10. Medtronic
11. Merit Medical Systems
12. NEXTBIOMEDICAL Co., Ltd.
13. PLMICROMED Co., Ltd.
14. QXMedical
15. SCITECH Medical
16. Serumwerk Bernburg AG
17. Siemens Healthineers
18. Sirtex Medical Limited
19. Suzhou Hengrui Medical Equipment Co., Ltd.
20. Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Liver Cancer and Embolization Case Volumes
  • 4.2.2 Shift Toward Minimally Invasive Embolization Over Surgery
  • 4.2.3 Advances in Radiopaque, Calibrated, and Drug-Eluting Particles
  • 4.2.4 Expansion of Hospital-To-Outpatient Embolization Workflows
  • 4.2.5 FDA Expansion of SIR-Spheres for Unresectable HCC
  • 4.2.6 Guideline Mainstreaming of Prostate Artery Embolization For BPH/LUTS
• 4.3 Market Restraints
  • 4.3.1 High Procedure Costs and Uneven Reimbursement
  • 4.3.2 Stringent Regulatory and Evidence Requirements
  • 4.3.3 Interventional Radiology Workforce Shortages
  • 4.3.4 Tariff-Driven Supply-Chain and Input-Cost Volatility
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Product Type
  • 5.1.1 Radioembolization Spheres
    • 5.1.1.1 Resin Microspheres
    • 5.1.1.2 Glass Microspheres
  • 5.1.2 Drug-Eluting Beads
    • 5.1.2.1 Doxorubicin-Loadable Beads
    • 5.1.2.2 Irinotecan-Loadable Beads
    • 5.1.2.3 Other Drug-Loadable Beads
  • 5.1.3 Embolic Microspheres
    • 5.1.3.1 Trisacryl Gelatin Microspheres
    • 5.1.3.2 PEG / Hydrogel Microspheres
    • 5.1.3.3 Acrylic / PMMA-Based Microspheres
  • 5.1.4 PVA Particles
  • 5.1.5 Gelfoam / Gelatin Sponge Particles
• 5.2 By Embolic Material
  • 5.2.1 Synthetic Materials
    • 5.2.1.1 Polyvinyl Alcohol
    • 5.2.1.2 Acrylic / PMMA
    • 5.2.1.3 PEG / Hydrogel
    • 5.2.1.4 Resin / Glass / Ceramic
  • 5.2.2 Natural Materials
    • 5.2.2.1 Gelatin
    • 5.2.2.2 Starch-Based
• 5.3 By Mode of Action
  • 5.3.1 Permanent
  • 5.3.2 Temporary / Resorbable
• 5.4 By Application
  • 5.4.1 Oncology
  • 5.4.2 Urology
  • 5.4.3 Gynecology
  • 5.4.4 Neurology
  • 5.4.5 Peripheral Vascular Disease and Hemorrhage Control
• 5.5 By End User
  • 5.5.1 Hospitals
  • 5.5.2 Ambulatory Surgical Centers
  • 5.5.3 Specialty Clinics
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East & Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 ABK Biomedical Inc.
  • 6.3.2 Boston Scientific Corporation
  • 6.3.3 Cardiolink Science (Shenzhen) Medical Technology Development Co., Ltd.
  • 6.3.4 Cook Medical LLC
  • 6.3.5 CrannMed Ltd.
  • 6.3.6 Endovastec (Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.)
  • 6.3.7 IMBiotechnologies Ltd.
  • 6.3.8 Instylla, Inc.
  • 6.3.9 Magle Pharmacept GmbH
  • 6.3.10 Medtronic plc
  • 6.3.11 Merit Medical Systems, Inc.
  • 6.3.12 NEXTBIOMEDICAL Co., Ltd.
  • 6.3.13 PLMICROMED Co., Ltd.
  • 6.3.14 QXMedical
  • 6.3.15 SCITECH Medical
  • 6.3.16 Serumwerk Bernburg AG
  • 6.3.17 Siemens Healthineers AG
  • 6.3.18 Sirtex Medical Limited
  • 6.3.19 Suzhou Hengrui Medical Equipment Co., Ltd.
  • 6.3.20 Terumo Corporation

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment